<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02302326</url>
  </required_header>
  <id_info>
    <org_study_id>AHM-MET-2013-01</org_study_id>
    <nct_id>NCT02302326</nct_id>
  </id_info>
  <brief_title>Involvement of Reticulum Endoplasmic Stress in the Physiopathology of Polycystic Ovary Syndrome</brief_title>
  <acronym>PI12/1984</acronym>
  <official_title>Involvement of Reticulum Endoplasmic Stress in the Physiopathology of Polycystic Ovary Syndrome: Possible Therapeutic Implications of Insulin Sensitizers.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of the present project is to evaluate the relevance of reticulum stress in
      the pathogenesis of polycystic ovary syndrome (PCOS), focusing particularly on the underlying
      mechanisms of insulin resistance, which is the origin of metabolic comorbidities.
      Furthermore, the investigators will assess the potential of insulin sensitizers as a
      treatment to control endoplasmic reticulum stress markers in PCOS patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To do this, the investigators will evaluate anthropometric, biochemical and hormone
      parameters, lipid profile and cardiovascular risk markers (using enzymatic and biochemical
      techniques, nephelometry, enzyme-linked immunosorbent assay, radioimmunoassay), and markers
      of endoplasmic reticulum stress and the insulin pathway and inflammatory and apoptotic
      parameters (by means of Western blot, Real Time- Polymerase Chain Reaction (RT-PCR), Luminex®
      xMAP® Technology ) in patients with and without PCOS. The investigators' second objective is
      to evaluate (using the abovementioned methodology) the efficacy of different insulin
      sensitizers (myoinositol and metformin) administered to PCOS patients during a 3-month period
      after which the investigators will analyze different parameters of oxidative stress and
      mitochondrial function (using Clark electrode and fluorometric techniques).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in markers of endoplasmic reticulum stress in controls and pcos women before and after metformin/Myo-inositol + folic acid administration</measure>
    <time_frame>3 months</time_frame>
    <description>Markers of endoplasmic reticulum stress (78-kDa glucose-regulated protein (GRP78), ubiquitous translation initiation factor 2α (eIF2α), double-stranded RNA-activated protein kinase (PERK), inositol requiring enzyme 1 (IRE1α), X-box binding protein 1 (XBP-1)) were assessed by Western Blot and Real Time- Polymerase Chain Reaction (RT-PCR) in polymorphonuclear cells</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in markers of the insulin pathway in controls and pcos women before and after metformin/Myo-inositol + folic acid administration</measure>
    <time_frame>3 months</time_frame>
    <description>Markers of the insulin pathway (c-Jun N-terminal kinase (JNK), insulin receptor substrate (IRS)) were assessed by Western Blot and Real Time- Polymerase Chain Reaction (RT-PCR) in polymorphonuclear cells</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in inflammatory parameters in controls and pcos women before and after metformin/Myo-inositol + folic acid administration</measure>
    <time_frame>3 months</time_frame>
    <description>Inflammatory parameters (nuclear factor κB (NF-κB), interleukin-6 (IL6), tumor necrosis factor α (TNFα)) were assessed by Western Blot, Real Time- Polymerase Chain Reaction (RT-PCR), or Luminex® xMAP® Technology in polymorphonuclear cells and serum</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in apoptotic parameters in controls and pcos women before and after metformin/Myo-inositol + folic acid administration</measure>
    <time_frame>3 months</time_frame>
    <description>Apoptotic parameters (transcription factor C/EBP homologous protein (CHOP) and caspase 12) were assessed by Western Blot and Real Time- Polymerase Chain Reaction (RT-PCR) in polymorphonuclear cells</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in anthropometric parameters in controls and pcos women before and after metformin/Myo-inositol + folic acid administration</measure>
    <time_frame>3 months</time_frame>
    <description>Anthropometric (weight, height, body mass index and waist) and blood pressure parameters were evaluated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in biochemical parameters in controls and pcos women before and after metformin/Myo-inositol + folic acid administration</measure>
    <time_frame>3 months</time_frame>
    <description>Glucose levels were measured using enzymatic techniques. Insulin was measured by an enzymatic luminescence technique. IR was calculated by homeostasis model assessment (HOMA). Total cholesterol and triglycerides were measured by employing enzymatic assays, and high density lipoprotein cholesterol (HDLc) concentrations were recorded with an autoanalyser using a direct method. Low-density lipoprotein cholesterol (LDLc) concentration was calculated using the Friedewald method. Luteinizing hormone (LH), follicle stimulating hormone (FSH) and testosterone were measured by specific radioimmunoassays. Dehydroepiandrosterone-sulfate (DHEAS), sex hormone-binding globulin (SHBG), androstenedione and testosterone were measured by specific chemiluminescence techniques. High-sensitive C-reactive protein (hsCRP) was quantified by a latex-enhanced immunonephelometric assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in mitochondrial function parameters in controls and pcos women before and after metformin/Myo-inositol + folic acid administration</measure>
    <time_frame>3 months</time_frame>
    <description>Oxidative stress markers ( mitochondrial oxygen (O2) consumption, membrane potential, glutathione, reactive oxygen species (ROS) and hydrogen peroxide levels, mitochondrial mass) were assessed by Clark electrode and fluorometric techniques</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in endothelial function parameters in controls and pcos women before and after metformin/Myo-inositol + folic acid administration</measure>
    <time_frame>3 months</time_frame>
    <description>Interactions between leukocytes and human umbilical vein endothelial cells were evaluated by flow chamber microscopy (leukocyte rolling velocity, leukocyte rolling flux and leukocyte adhesion). The vascular cell adhesion molecule 1 (VCAM-1), Intercellular adhesion molecule 1 (ICAM-1) and E-selectin were evaluated in serum by Luminex® 200 flow analyzer system</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Polycystic Ovary Syndrome</condition>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PCOS women began treatment with ER 500 mg metformin per day, and the dose was increased to 1000 mg after 2 weeks, and to 1700 mg/d after a further 2 weeks, and was maintained at this dose for a total of 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Myo-inositol + folic acid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PCOS women received a dietary supplement (Ovusitol® : 4 g myo-inositol plus 400 micrograms of folic acid) for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy women</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Healthy untreated women adjusted for age and body mass index</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Dose: metformin (1700 mg / day) for 12 weeks</description>
    <arm_group_label>Metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Myo-inositol + folic acid</intervention_name>
    <description>Dose: Ovusitol® (4 g myo-inositol plus 400 micrograms of folic acid/day) for 12 weeks</description>
    <arm_group_label>Myo-inositol + folic acid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women diagnosed with PCOS using the Rotterdam criteria

          -  Women of reproductive age

        Exclusion Criteria:

          -  Organic, malignant, haematological, infectious or inflammatory disease

          -  History of ischaemic heart disease (stroke or thromboembolism)

          -  Diabetes mellitus,

          -  Secondary causes of obesity (hypothyroidism, Cushing's syndrome)

          -  Severe hypertension.

          -  Smoking or alcohol habit
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonio Hernández, Phd, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>FISABIO - University Hospital Dr Peset</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Antonio Hernández, Phd, MD</last_name>
    <phone>34961622492</phone>
    <email>hernandez_antmij@gva.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Vanessa Rodenas</last_name>
    <phone>34961925963</phone>
    <email>rodenas_van@gva.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Antonio Hernández</name>
      <address>
        <city>Valencia</city>
        <zip>46017</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Hernández, Phd, MD</last_name>
      <phone>34961622492</phone>
      <email>hernandez_antmij@gva.es</email>
    </contact>
    <contact_backup>
      <last_name>Celia Bañuls, PhD</last_name>
      <phone>34961622757</phone>
      <email>celia.banuls@uv.es</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Hernández-Mijares A, Bañuls C, Gómez-Balaguer M, Bergoglio M, Víctor VM, Rocha M. Influence of obesity on atherogenic dyslipidemia in women with polycystic ovary syndrome. Eur J Clin Invest. 2013 Jun;43(6):549-56. doi: 10.1111/eci.12080. Epub 2013 Mar 26.</citation>
    <PMID>23528141</PMID>
  </reference>
  <reference>
    <citation>Victor VM, Rocha M, Bañuls C, Alvarez A, de Pablo C, Sanchez-Serrano M, Gomez M, Hernandez-Mijares A. Induction of oxidative stress and human leukocyte/endothelial cell interactions in polycystic ovary syndrome patients with insulin resistance. J Clin Endocrinol Metab. 2011 Oct;96(10):3115-22. doi: 10.1210/jc.2011-0651. Epub 2011 Jul 21.</citation>
    <PMID>21778215</PMID>
  </reference>
  <reference>
    <citation>Victor VM, Rocha M, Bañuls C, Sanchez-Serrano M, Sola E, Gomez M, Hernandez-Mijares A. Mitochondrial complex I impairment in leukocytes from polycystic ovary syndrome patients with insulin resistance. J Clin Endocrinol Metab. 2009 Sep;94(9):3505-12. doi: 10.1210/jc.2009-0466. Epub 2009 Jun 30.</citation>
    <PMID>19567514</PMID>
  </reference>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 29, 2014</study_first_submitted>
  <study_first_submitted_qc>November 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 27, 2014</study_first_posted>
  <last_update_submitted>February 14, 2017</last_update_submitted>
  <last_update_submitted_qc>February 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana</investigator_affiliation>
    <investigator_full_name>Antonio Hernandez Mijares</investigator_full_name>
    <investigator_title>PhD, MD</investigator_title>
  </responsible_party>
  <keyword>reticulum endoplasmic stress</keyword>
  <keyword>Polycystic Ovary Syndrome</keyword>
  <keyword>mitochondrial function</keyword>
  <keyword>insulin resistance</keyword>
  <keyword>inflammation</keyword>
  <keyword>myoinositol</keyword>
  <keyword>metformin</keyword>
  <keyword>oxidative stress</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Folic Acid</mesh_term>
    <mesh_term>Vitamin B Complex</mesh_term>
    <mesh_term>Inositol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

